{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:55:09Z","timestamp":1792090509502,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Immigrant Minority Health"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Community health centers (CHC) play a key role in latent tuberculosis infection (LTBI) testing and treatment. We performed a retrospective analysis of LTBI testing and treatment among pediatric and adult patients at a CHC with a large non-U.S.-born (USB) population during a series of quality improvement (QI) interventions from 2010 to 2019. Among 124,695 patients with primary care visits, 40% of patients were tested for tuberculosis (TB) infection and among those tested, 20% tested positive, including 39% of adults aged 50\u201379\u00a0years. Compared to adults aged 18\u201349\u00a0years, children aged 6\u201317 had increased odds of LTBI testing and treatment initiation [odds ratio and 95% confidence interval 3.23 (3.10, 3.36) and 1.41 (1.12, 1.79), respectively], while age\u2009\u2265\u200965 was associated with lower odds of both testing and treatment initiation. Over the analysis period, coinciding with unfunded QI interventions intended to reduce barriers to LTBI care, there was a significant increase in the proportion of patients receiving LTBI testing for both adults (6% to 47%, p\u2009&lt;\u20090.001) and children (23% to 80%, p\u2009&lt;\u20090.001). During the analysis period, there was also a significant increase in the proportion of patients receiving prescriptions for LTBI treatment, as well as provider use of evidence-based strategies including rifamycin-based treatment. Our study suggests that primary care interventions can reduce barriers to LTBI treatment and drive TB elimination.<\/jats:p>","DOI":"10.1007\/s10903-022-01438-1","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:02:57Z","timestamp":1674039777000},"page":"803-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Can Primary Care Drive Tuberculosis Elimination? Increasing Latent Tuberculosis Infection Testing and Treatment\u00a0Initiation at a Community Health Center with a Large Non-U.S.-born Population"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8151-2686","authenticated-orcid":false,"given":"Amy S.","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinnia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen S.","family":"Katrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"1438_CR1","volume-title":"Global tuberculosis report 2021","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021."},{"key":"1438_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.15585\/mmwr.mm6911a3","volume":"69","author":"NG Schwartz","year":"2020","unstructured":"Schwartz NG, Price SF, Pratt RH, Langer AJ. Tuberculosis\u2014United States, 2019. Morb Mortal Wkly Rep. 2020;69:286\u20139.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"9","key":"1438_CR3","doi-asserted-by":"publisher","first-page":"e2014481","DOI":"10.1001\/jamanetworkopen.2020.14481","volume":"3","author":"C Lee-Rodriguez","year":"2020","unstructured":"Lee-Rodriguez C, Wada PY, Hung Y, Skarbinski J. Association of mortality and years of potential life lost with active tuberculosis in the United States. JAMA Netw Open. 2020;3(9):e2014481.","journal-title":"JAMA Netw Open"},{"key":"1438_CR4","unstructured":"California Tuberculosis Elimination Advisory Committee. California tuberculosis elimination plan 2021\u20132025. 2021."},{"issue":"S4","key":"1438_CR5","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.2105\/AJPH.2018.304529","volume":"108","author":"S Katrak","year":"2018","unstructured":"Katrak S, Flood J. Latent tuberculosis and current health disparities in California: making the invisible visible. Am J Public Health. 2018;108(S4):S242\u20135. https:\/\/doi.org\/10.2105\/AJPH.2018.304529.","journal-title":"Am J Public Health"},{"key":"1438_CR6","volume-title":"Report on tuberculosis in California, 2019","author":"Tuberculosis Control Branch","year":"2020","unstructured":"Tuberculosis Control Branch. Report on tuberculosis in California, 2019. Sacramento: California Department of Public Health; 2020."},{"issue":"9","key":"1438_CR7","doi-asserted-by":"publisher","first-page":"e3476","DOI":"10.1093\/cid\/ciaa857","volume":"73","author":"Y Jo","year":"2021","unstructured":"Jo Y, Shrestha S, Gomes I, Marks S, Hill A, Asay G, Dowdy D. Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York, and Texas. Clin Infect Dis. 2021;73(9):e3476\u201382.","journal-title":"Clin Infect Dis"},{"key":"1438_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/aje\/kwt246","volume":"179","author":"KM Shea","year":"2014","unstructured":"Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014;179:216\u201325.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"1438_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2016.11046","volume":"316","author":"US Preventive Services Task Force","year":"2016","unstructured":"US Preventive Services Task Force. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316(9):962\u20139.","journal-title":"JAMA"},{"key":"1438_CR10","volume-title":"California adult tuberculosis risk assessment and user guide (september 2018)","author":"California Department of Public Health","year":"2018","unstructured":"California Department of Public Health. California adult tuberculosis risk assessment and user guide (september 2018). Sacramento: California Department of Public Health; 2018."},{"key":"1438_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020. Morb Mortal Wkly Rep. 2020;69:1\u201311.","journal-title":"Morb Mortal Wkly Rep"},{"key":"1438_CR12","unstructured":"Division of Tuberculosis Elimination. Latent tuberculosis infection: a guide for primary health care providers. Centers for Disease Control and Prevention National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention 2020;22-0468."},{"issue":"5","key":"1438_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1714283.","journal-title":"N Engl J Med"},{"issue":"11","key":"1438_CR14","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"H Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1438_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10903-020-01047-w","volume":"23","author":"C Prater","year":"2021","unstructured":"Prater C, Holzman S, Shah M. Programmatic effectiveness of latent tuberculosis care cascade in a Community Health Center. J Immigr Minor Health. 2021;23(3):566\u201373.","journal-title":"J Immigr Minor Health"},{"issue":"9","key":"1438_CR16","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1097\/INF.0b013e318257f7c6","volume":"31","author":"J Young","year":"2012","unstructured":"Young J, Edick T, Klee D, O\u2019Connor M. Successful treatment of pediatric latent tuberculosis infection in a community health center clinic. Pediatr Infect Dis J. 2012;31(9):e147\u201351.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"1438_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/NCQ.0000000000000579","volume":"37","author":"FN Truax","year":"2022","unstructured":"Truax FN, Low J, Mochizuki T, Asfaha S, Nguyen TN, Carson M, Katrak S, Shah N, Nguyen D. Latent tuberculosis infection testing and treatment at a federally qualified health center in Southern California: a quality improvement project. J Nurs Care Qual. 2022;37(2):155\u201361.","journal-title":"J Nurs Care Qual"},{"key":"1438_CR18","unstructured":"United States, Department of Health and Human Services, Centers for Disease Control and Prevention. Tuberculin skin testing fact sheet. Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/testing\/skintesting.htm. Accessed 27 Sept 2022."},{"key":"1438_CR19","unstructured":"Tuberculosis Control Program. Policy for tuberculosis screening requirement at preschool and TK\/K-12 school entry. City and County of San Francisco Population Health Division Department of Public Health. 2019. https:\/\/www.sfcdcp.org\/wp-content\/uploads\/2018\/01\/SF-Schools_TB_Entry_Policy_220190304.pdf. Accessed 23 Feb 2022."},{"key":"1438_CR20","unstructured":"Santa Clara County Public Health. Tuberculosis information for health care providers and schools. County of Santa Clara Public Health Department. 2019. https:\/\/publichealthproviders.sccgov.org\/sites\/g\/files\/exjcpb951\/files\/documents\/tb-providers-schools.pdf. Accessed 23 Feb 2022."},{"key":"1438_CR21","unstructured":"San Mateo-Foster City School District. Tuberculosis testing. 2019. http:\/\/www.gamutonline.net\/district\/sanmateofostercity\/displayPolicy\/1159242\/5. Accessed 23 Feb 2022."},{"issue":"8","key":"1438_CR22","first-page":"224","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection\u2014United States, 2004\u20132008. Morb Mortal Wkly Rep. 2010;59(8):224\u20139.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"9","key":"1438_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jama.2016.10357","volume":"316","author":"LC Kahwati","year":"2016","unstructured":"Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, Weber RP, Jonas DE. Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(9):970\u201383.","journal-title":"JAMA"},{"issue":"12","key":"1438_CR24","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1086\/647944","volume":"49","author":"PD Ziakas","year":"2009","unstructured":"Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009;49(12):1883\u20139.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"1438_CR25","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","volume":"166","author":"KR Page","year":"2006","unstructured":"Page KR, Sifakis F, de Oca RM, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863\u201370.","journal-title":"Arch Intern Med"},{"key":"1438_CR26","first-page":"3816432","volume":"2017","author":"K Owusu-Edusei Jr","year":"2017","unstructured":"Owusu-Edusei K Jr, Winston CA, Marks SM, Langer AJ, Miramontes R. Tuberculosis test usage and medical expenditures from outpatient insurance claims data, 2013. Tuberc Res Treat. 2017;2017:3816432.","journal-title":"Tuberc Res Treat"},{"issue":"12","key":"1438_CR27","doi-asserted-by":"publisher","first-page":"e0243102","DOI":"10.1371\/journal.pone.0243102","volume":"15","author":"EL Stockbridge","year":"2020","unstructured":"Stockbridge EL, Loethen AD, Annan E, Miller TL. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: evidence from commercial insurance data. PLoS ONE. 2020;15(12):e0243102.","journal-title":"PLoS ONE"},{"issue":"5","key":"1438_CR28","doi-asserted-by":"publisher","first-page":"e0268739","DOI":"10.1371\/journal.pone.0268739","volume":"17","author":"A Readhead","year":"2022","unstructured":"Readhead A, Flood J, Barry P. Health insurance, healthcare utilization and language use among populations who experience risk for tuberculosis, California 2014\u20132017. PLoS ONE. 2022;17(5):e0268739. https:\/\/doi.org\/10.1371\/journal.pone.0268739.","journal-title":"PLoS ONE"},{"issue":"6","key":"1438_CR29","doi-asserted-by":"publisher","first-page":"684","DOI":"10.5588\/ijtld.16.0617","volume":"21","author":"K Owusu-Edusei","year":"2017","unstructured":"Owusu-Edusei K, Stockbridge EL, Winston CA, Kolasa M, Miramontes R. Tuberculin skin test and interferon-gamma release assay use among privately insured persons in the United States. Int J Tuberc Lung Dis. 2017;21(6):684\u20139. https:\/\/doi.org\/10.5588\/ijtld.16.0617.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1438_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1472-6963-11-247","volume":"11","author":"A Nienhaus","year":"2011","unstructured":"Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11:247. https:\/\/doi.org\/10.1186\/1472-6963-11-247.","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"1438_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3122\/jabfm.2012.05.110281","volume":"25","author":"EK Shaw","year":"2012","unstructured":"Shaw EK, Howard J, West DR, Crabtree BF, Nease DE, Tutt B, Nutting PA. The role of the champion in primary care change efforts: from the State Networks of Colorado Ambulatory Practices and Partners (SNOCAP). J Am Board Fam Med. 2012;25(5):676\u201385.","journal-title":"J Am Board Fam Med"},{"key":"1438_CR32","unstructured":"Preventing tuberculosis in your clinical setting: a practical guidebook. California Department of Public Health. 2022. https:\/\/ctca.org\/wp-content\/uploads\/Preventing-TB-in-Your-Clinical-Setting-A-Practical-Guidebook.pdf. Accessed May 2022."}],"container-title":["Journal of Immigrant and Minority Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10903-022-01438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10903-022-01438-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10903-022-01438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T16:29:35Z","timestamp":1688056175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10903-022-01438-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s10903-022-01438-1","relation":{},"ISSN":["1557-1912","1557-1920"],"issn-type":[{"value":"1557-1912","type":"print"},{"value":"1557-1920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"7 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Association of Asian Pacific Community Health Organizations (AAPCHO) Institutional Review Board, which accepted our waiver of informed consent, as our research was a retrospective analysis of data that was de-identified and summarized in aggregate, which posed minimal risk to participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This retrospective research involved human participants, whose names and medical record numbers were replaced with study identification numbers prior to sharing with study collaborators to mitigate risk of inadvertent disclosure of personal health information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human and Animal Rights"}}]}}